Compare ETS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETS | BIVI |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.7M | 12.7M |
| IPO Year | 2025 | 2013 |
| Metric | ETS | BIVI |
|---|---|---|
| Price | $2.44 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.26 |
| AVG Volume (30 Days) | 45.3K | ★ 193.8K |
| Earning Date | 10-14-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.83 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,665,948.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.57 | N/A |
| 52 Week Low | $0.39 | $0.82 |
| 52 Week High | $2.75 | $3.79 |
| Indicator | ETS | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 68.71 | 40.77 |
| Support Level | $0.47 | $1.14 |
| Resistance Level | $2.75 | $1.32 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 89.09 | 34.21 |
Elite Express Holding Inc is a holding company that operates through its wholly owned subsidiary and specializes in last-mile delivery services within California. Its core business focuses on retrieving packages from distribution hubs and ensuring their prompt and secure delivery to recipients doorsteps. Committed to innovation and efficiency, its mission is to optimize last-mile logistics by providing efficient, reliable delivery solutions. The company mainly competes in the route delivery industry, which has several material barriers of entry, including: Substantial time and capital investment, Technological proficiency, Regulatory barriers, Balancing service quality and cost efficiency, and Effective Management.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.